P1, N=78, Terminated, Pfizer | N=130 --> 78 | Trial completion date: Sep 2025 --> Nov 2023 | Recruiting --> Terminated | Trial primary completion date: Sep 2025 --> Nov 2023; Study was terminated due to strategic considerations and not due to safety.

3 months ago

Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Metastases

Avastin (bevacizumab) • sasanlimab (PF-06801591) • PF-07062119

almost3years

Preclinical Evaluation of Zr-Df-IAB22M2C PET as an Imaging Biomarker for the Development of the GUCY2C-CD3 Bispecific PF-07062119 as a T Cell Engaging Therapy. (PubMed, Mol Imaging Biol)

Immune-imaging technologies for quantitative cellular measures would be a valuable biomarker in immunotherapeutic clinical development. We demonstrated a qualification of Zr-IAB22M2C PET to evaluate PD responses (mice) to a novel immunotherapeutic.

almost 3 years ago

Preclinical • Journal • IO biomarker

CD8 (cluster of differentiation 8)

PF-07062119

almost4years

[VIRTUAL] A novel GUCY2C - CD3 bispecific engages T cells to induce cytotoxicity in gastrointestinal tumors (AACR-II 2020)

These data highlight the potential for PF-07062119 to demonstrate efficacy and improve patient outcomes in CRC and other gastrointestinal malignancies. A clinical Phase I study has been initiated in patients with CRC, gastric and esophageal adenocarcinomas (NCT04171141).

almost 4 years ago

PD(L)-1 Biomarker • IO biomarker

KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene)

KRAS mutation • BRAF mutation

PF-07062119

over4years

A Novel GUCY2C-CD3 T cell Engaging Bispecific construct (PF-07062119) for the Treatment of Gastrointestinal Cancers. (PubMed, Clin Cancer Res)

These data highlight the potential for PF-07062119 to demonstrate efficacy and improve patient outcomes in CRC and other gastrointestinal malignancies.

over 4 years ago

Journal • PD(L)-1 Biomarker

KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene)

PF-07062119